HC Wainwright Comments on Nuvectis Pharma Q1 Earnings

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Nuvectis Pharma in a research note issued to investors on Wednesday, February 11th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings per share of ($0.29) for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Nuvectis Pharma’s Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.31) EPS and Q4 2026 earnings at ($0.32) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Nuvectis Pharma in a research note on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $15.33.

Nuvectis Pharma Stock Performance

Shares of NVCT stock opened at $8.80 on Thursday. The firm has a fifty day moving average of $8.14 and a 200-day moving average of $6.94. The stock has a market cap of $225.37 million, a price-to-earnings ratio of -6.67 and a beta of -0.29. Nuvectis Pharma has a 52-week low of $5.55 and a 52-week high of $11.52.

Nuvectis Pharma (NASDAQ:NVCT) last issued its earnings results on Wednesday, February 11th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.05).

Institutional Trading of Nuvectis Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of NVCT. Vanguard Group Inc. lifted its holdings in Nuvectis Pharma by 4.8% during the 3rd quarter. Vanguard Group Inc. now owns 698,708 shares of the company’s stock worth $4,206,000 after buying an additional 31,903 shares in the last quarter. Iridian Asset Management LLC CT raised its position in shares of Nuvectis Pharma by 44.5% during the fourth quarter. Iridian Asset Management LLC CT now owns 586,320 shares of the company’s stock worth $4,427,000 after acquiring an additional 180,699 shares during the last quarter. Baldwin Wealth Partners LLC MA lifted its stake in shares of Nuvectis Pharma by 11.2% during the fourth quarter. Baldwin Wealth Partners LLC MA now owns 389,625 shares of the company’s stock valued at $2,942,000 after acquiring an additional 39,164 shares during the period. Geode Capital Management LLC boosted its holdings in Nuvectis Pharma by 11.8% in the fourth quarter. Geode Capital Management LLC now owns 364,024 shares of the company’s stock valued at $2,749,000 after acquiring an additional 38,291 shares during the last quarter. Finally, Oppenheimer & Co. Inc. boosted its holdings in Nuvectis Pharma by 6.5% in the fourth quarter. Oppenheimer & Co. Inc. now owns 73,566 shares of the company’s stock valued at $555,000 after acquiring an additional 4,500 shares during the last quarter. Institutional investors and hedge funds own 96.77% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.